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The ability of simian virus 40-encoded large T antigen to disrupt the growth control of a variety of cell types
is related to its ability to interfere with certain cellular proteins, such as p53 and the retinoblastoma
susceptibility gene product (pRB). We have used wild-type and mutant forms of T antigen in transgenic mice
to dissect the roles of pRB, p53, and other cellular proteins in tumorigenesis of different cell types. In this
study, using a cell-specific promoter to target expression specifically to brain epithelium (the choroid plexus)
and to B and T lymphoid cells, we characterize the tumorigenic capacity of a T-antigen fragment that comprises
only the amino-terminal 121 residues. This fragment (d11137) retains the ability to interact with pRB and p107
but lacks the p53-binding domain. While loss of the p53-binding region results in loss of the capacity to induce
lymphoid abnormalities, d11137 retains the ability to induce choroid plexus tumors that are histologically
indistinguishable from those induced by wild-type T antigen. Tumors induced by d11137 develop much more
slowly, however, reaching an end point at around 8 months of age rather than at 1 to 2 months. Analysis of
tumor progression indicates that tumor induction by d11137 does not require secondary genetic or epigenetic
events. Rather, the tumor growth rate is significantly slowed, indicating that the T-antigen C-terminal region
contributes to tumor progression in this cell type. In contrast, the pRB-binding region appears essential for
tumorigenesis as mutation of residue 107, known to disrupt pRB and p107 binding to wild-type T antigen,
abolishes the ability of the d11137 protein to induce growth abnormalities in the brain.
Transgenic mice provide a valuable system with which to
explore mechanisms that regulate cell growth and differentia-
tion. The ability to target the expression of test genes to
specific cell types and developmental stages facilitates the
rigorous assessment of regulatory pathways operative in each
cell type in vivo. By this approach, simian virus 40 (SV40)
large-T-antigen protein has been shown to be a particularly
potent oncogene product that can disrupt the growth of more
than 20 distinct cell types in mice (1, 28, 29). The molecular
mechanisms by which the 708-amino acid (aa) multifunctional
T antigen subverts normal cell growth remain largely unknown,
although correlations between transforming activity in cultured
cells and the binding to specific cellular proteins have provided
some clues. Studies in cell culture (reviewed in reference 23)
and more recently in transgenic mice (5, 73) suggest that
multiple distinct activities of T antigen are involved in growth
disregulation. At least two transformation-related functions
map within the amino-terminal 121 residues. The better-
characterized of these corresponds to a domain (aa 105 to 114)
that interacts with cellular proteins pRB (13) and p107 (19,
21). A second, distinct transformation-related activity appears
to lie within the first 82 aa (54, 70, 73, 83), but the associated
biochemical properties have not been defined. Complementa-
tion studies indicate that this region may interact with the
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adenovirus ElA-associated host protein, p300 (78). Interaction
of the N terminus with a 185-kDa protein has also recently
been observed (65). A third T-antigen transformation function
resides in the C-terminal half of the protein and corresponds to
the p53-binding activity (lying within aa 351 to 626 [38, 51, 57,
63, 82]). Recent evidence suggests that other, less well charac-
terized functions of T antigen could also participate in trans-
formation (16). Although each of these T-antigen activities can
be related to growth disregulation in one or another experi-
mental system, their relative importance in cultured cells often
depends on the particular cell line, cellular environment,
and/or biological assay used (e.g., references 16, 23, 54, 68, 70,
74, and 83). As illustrated here, transgenic mice offer an
alternative for evaluating the effects of this multipotent onco-
protein under natural cellular conditions.
Despite intensive investigation, the normal biological roles
of p53 and pRB proteins are not clear. Both are thought to
have roles in cell cycle control (for recent reviews, see refer-
ences 27, 33, 41, 47, 60, and 62; see Discussion). The classifi-
cation of p53 and pRB as negative growth regulators or tumor
suppressors comes from the observations that the genes en-
coding these proteins often are lost or mutated in certain
human tumors and that upon transfection into certain cultured
cells, both genes can produce effects associated with the
inhibition of cell growth (for reviews, see references 2, 27, 45,
47, 53, and 77). Within that general framework, it has been
postulated that the ability ofT antigen (and certain other DNA
tumor virus proteins) to stimulate cell growth reflects the
release of a brake to cell growth normally imposed by proteins
such as p53 and pRB (58). But that interpretation awaits
experimental definition and verification.
Examining the various activities of T antigen in tumorigen-
esis provides a way to explore the normal function of its target
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proteins, such as pRB and p53. With this purpose in mind, we
have developed a transgenic mouse system in which T-antigen
mutants that differ in their cellular protein-binding capacities
are examined for tumorigenic activity in particular cell types.
The system uses the cell-specific transcriptional control region
from lymphotropic papovavirus (LPV) to direct expression to
three cell types: the choroid plexus epithelium (CPE) of the
brain, and B and T lymphoid cells (4-6, 20). In this system,
wild-type SV40 T antigen expressed from the LPV promoter
induces choroid plexus tumors in the majority of founder mice
by around 4 weeks of life, apparently without the need for
secondary somatic changes (6). Under circumstances in which
the rapid development of CPE tumors (and resulting death of
the animals) does not occur, wild-type T antigen also causes
lymphoma of both B and T cells (4, 5, 24, 71). Our follow-up
studies with mutant versions of T antigen have begun to dissect
the particular regions of the viral protein, and thus the target
cellular proteins, required for tumorigenesis in these three cell
types (5, 73, 76).
Here we describe analyses carried out with mutant dl1137,
which produces a form of T antigen (aa 1 to 121) that includes
the pRB/p107-binding domain but lacks the p53-binding re-
gion. We were intrigued by preliminary evidence suggesting
that this severely truncated version of T antigen was not devoid
of activity. Thus, dl137 and similar mutants were able to
transform some albeit not all lines of cultured cells (66-68, 70).
Our preliminary analysis of a small number of founder trans-
genic mice also indicated that this fragment of T antigen could
induce choroid plexus tumors but within a significantly delayed
time frame compared with those induced by wild-type T
antigen (5). Although this experiment indicated that d1137
could somehow participate in tumorigenesis of at least one cell
type, it did not allow us to determine the contributions of
specific N-terminal and C-terminal functions to tumor devel-
opment. For example, were compensating secondary somatic
mutations of cellular factors required for tumor induction by
dli 137? If not, did the C-terminal region (including the
p53-binding region) contribute in any way to brain tumor
development? Is the pRB/p107-binding region a critical factor
in brain tumor induction by the amino-terminal fragment? Is
the tumorigenic activity of dl1137 cell specific? These and
other related issues are addressed in the following experi-
ments.
MATERIALS AND METHODS
Plasmids. The construction of pLST and pLST1137 (carry-
ing the LPV control region driving the wild-type and the
amino-terminal SV40 T-antigen-coding regions, respectively)
was previously described (5, 6). Plasmid pLST1137K1 (a hybrid
between the LPV control region and the 1137K1 coding
region) is identical to pLST1 137 except that it contains a single
nucleotide change (C-4500 to T). It was constructed from
plasmids pLPVEN (4, 5) and p1137K1. Plasmid p1137K1
contains the 1137At coding region in the pTZ-19U phagemid
vector background. The point mutation resulting in a glutamic
acid-to-lysine change of residue 107 was introduced by site-
directed mutagenesis, performed by using the phagemid sys-
tem supplied by Bio-Rad. The full SV40 T-antigen-coding
region (StuI-to-BamHI fragment) was cloned into the phage-
mid for mutagenesis. The Kl point mutation was introduced by
using a primer of the following sequence: 5'"TG CTC AAA
AGA AAT GCC AT3' (the G-to-A mutation is underlined).
Conditions for mutagenesis and for phage and phagemid
growth were as suggested by Bio-Rad. The EcoRI to Asp 718
fragment from pLPV-EN (containing the LPV region) was
isolated and inserted into the EcoRI and Asp 718 sites of
p1137K1 to generate pLST1137K1. The entire d11137K1-
coding region was confirmed by sequence analysis of pLST
1137K1.
Production and screening of transgenic mice. LST mice
harbor the wild-type large-T-antigen-coding region under LPV
transcriptional control and have been previously described (6).
The fusion genes from both LST1137 and LST1137K1 were
isolated after digestion of the corresponding plasmids with
EcoRI and Sall. Fragment purification and the production and
screening of transgenic mice were carried out as described
previously (4, 32). The final DNA concentrations were ad-
justed to 4 ,ug/ml. Single-cell embryos were obtained from a
cross between B6D2F1 (C57B16/J x DBA2; The Jackson
Laboratory) mice.
Antibodies. Monoclonal antibodies specific for SV40 T
antigen, PAb419 (30) and PAb1O8 (26), have been described
previously. The epitope recognized by PAb419 maps to the first
60 aa of SV40 T antigen, and that recognized by PAb1O8 mnaps
to the first 100 aa. PAb421 is a monoclonal antibody directed
against mouse p53. All monoclonal antibodies were prepared
as tissue culture supernatants or further concentrated by using
standard protein A-Sepharose columns (Pharmacia).
For the in situ detection of dll137 and dll137K1 proteins,
specific antibodies were purified from a hamster polyclonal
anti-large-T-antigen ascites (43). Antibody was first enriched
by using protein A-Sepharose columns. Subsequently, 2 mg of
affinity-purified, baculovirus-encoded dll137 protein (a kind
gift of J. Pipas) was diluted in 5 ml of 20 mM Tris-150 mM
glycine (pH 8.0) and spotted onto a nitrocellulose filter (1.5 by
3 cm; Schleicher & Schuell, Inc.). The filter was treated for 30
min with 3% bovine serum albumin (BSA)-5% powdered milk
in 10 mM Tris-HCI (pH 8.0)-150 mM NaCl-0.2% Tween 20
(TST) and then incubated for 1 h with 1 ml of anti-SV40
T-antigen hamster ascites fluid diluted 1:2 in TST-3%
BSA-5% powdered milk. After five 5-min washes with TST,
bound antibody was eluted by incubating the filter in 1 ml of
100 mM glycine-HCl (pH 3.0) for 60 s. The eluate was
neutralized by adding 1/10 volume of 1 M Tris-HCl (pH 8.0).
The filter was washed twice for 5 min each time with TST, and
then blocking, absorption, and elution were repeated when
necessary. All incubations were carried out at 25°C. Eluates
were supplemented with 10% normal horse serum (Vector)
and stored in aliquots at - 20°C.
Histology and immunohistochemistry. For routine histol-
ogy, tissues were fixed with Bouin's fixative for 1 h and
embedded with paraffin. Five-micrometer sections were
stained with hematoxylin and eosin (37). Tissues used for
immunohistochemistry were frozen in liquid nitrogen and
stored at - 80°C. Eight-micrometer sections were prepared by
using a cryostat at - 20°C, on positively charged slides (Probe-
On; FisherBiotech), fixed in 2% formaldehyde in TS buffer (50
mM Tris-HCl [pH 7.6], 150 mM NaCl) for 2 min, washed twice
with TS buffer, dehydrated in ethanol for 10 min at 4°C, and
transferred to TS buffer containing 0.2% Nonidet P-40 (NP-
40) for 5 min at 4°C. After three washes with TS buffer, the
sections were incubated with primary antibody (protein A-pu-
rified hamster polyclonal antibody specific to SV40 T antigen,
prepared as described above) for 1.5 h. After three washes with
TS buffer and incubation for 1 h with secondary antibody
(biotinylated goat anti-hamster immunoglobulin G; Pierce),
the sections were stained by the Vectastain ABC method as
specified by Vector Laboratories. Immune complexes were
detected by incubation with horseradish peroxidase-avidin
complex (Vector) and diaminobenzidine substrate. Dilution of
antibodies was in TS buffer supplemented with 10% normal
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goat serum (Vector). All steps were performed at 25°C unless
specified.
Immunodetection of S-phase cells. S-phase cells in tissue
sections were detected by using the cell proliferation kit from
Amersham, with minor modifications. Mice were injected
intraperitoneally with 5-bromo-2'-deoxyuridine (BrdU; 0.01
ml/g) and sacrificed after 2 h. Brains were dissected and
processed as described above for immunohistochemistry. After
the initial TS buffer washes, the sections were incubated for 1
h with 10% normal goat serum (Vector) and then transferred
to nuclease-anti-BrdU as suggested for an additional hour.
Following three additional washes in TS buffer and incubation
for 1 h with antimouse immunoglobulin G2a-peroxidase, the
samples were stained with diaminobenzidine as the substrate.
All steps were performed at 25°C. After brief counterstaining
with eosin (0.25%, 2 min), the sections were washed with
distilled H20, dehydrated with 70% ethanol, and mounted for
analysis.
Immunoprecipitation and immunoblotting analysis. Tissues
were stored frozen at - 80°C prior to analysis. Samples (about
0.2 g) were suspended in 2 ml of lysis buffer containing 50 mM
Tris (pH 8.0), 5 mM EDTA, 150 mM NaCl, and 0.5% NP-40.
Protease inhibitors phenylmethylsulfonyl fluoride (25 mg/ml),
leupeptin (0.5 mg/ml), and pepstatin (0.7 mg/ml) were in-
cluded in the lysis buffer (Boehringer Mannheim Biochemi-
cals). Tissues were homogenized and sonicated for 10 s on ice.
The tissue extracts were cleared twice by centrifugation at 735
x g for 10 to 15 min. Protein determinations, immunoprecipi-
tation reactions, and polyacrylamide denaturing gel electro-
phoresis were performed as described previously (72).
Proteins were transferred to nitrocellulose (Bio-Rad) for 7 h
to overnight at 25 V in 20 mM Tris-150 mM glycine-20%
methanol. Filters were air dried, rinsed in TBS-NP-40 (0.2 M
NaCl, 50 mM Tris-Cl [pH 7.4], 0.1% NP-40), and blocked with
3% BSA and 5% dry milk powder in TBS-NP-40 for 1 h.
Filters were incubated for 1 h at room temperature with
monoclonal supernatants or an appropriate primary antibody
dilution. The optimal antibody concentrations were estimated
by testing serial dilutions for their capacity to detect purified
standard amounts of dll 137 protein spotted into nitrocellulose
paper. Following each antibody incubation, filters were washed
three times with TBS-NP-40. The filters were then incubated
for 1 h at room temperature with a 1:3,000 dilution of protein
A-conjugated horseradish peroxidase (Zymed). All antibodies
were diluted in TBS-NP-40 supplemented with 3% BSA and
5% dry milk powder. Following incubation, the filters were
rinsed as described above. Specific reactions were detected as
recommended, using the ECL (enhanced chemiluminescence)
system (Amersham).
RESULTS
T-antigen amino-terminal fragment induces a cell-specific
response in transgenic mice. To fully characterize the role of
d11137 in choroid plexus tumorigenesis and to determine its
effect in the lymphoid system, seven additional LST1137
founder mice and two independent families of mice were
generated for analysis. The LST1137 transgene encodes the
dll137 protein under control of the LPV transcriptional signals
(Fig. 1A; see the introduction). In transgenic mice, this regu-
latory region consistently directs expression to the B and T
lymphocytes and to the CPE (4, 6). The LST1137 transgene
does not encode small t antigen as a result of removal of the
small t-specific splice donor site (see Materials and Methods).
The T antigen expressed by LST1137 is truncated after residue
121 as a result of a small out-of-frame deletion which also
results in the addition of 11 missense residues (61, 70). This
form of T antigen binds pRB (70a) but lacks the p53-binding
region (Fig. 1B). Moreover, although T antigen normally
stabilizes p53 (46), d11137 does not (60a).
Of nine founder mice generated with the LST1137 transgene
in a previous study, four mice developed an abnormally
enlarged choroid plexus leading to hydrocephaly in two mice
and overt tumors in two mice (5) (Table 1, LST1137-1 through
-4). Of the additional seven founder mice produced in this
study, four mice developed choroid plexus tumors (Table 1,
LST1137-5 through -8). Extensive expansion of the choroid
plexus, often accompanied by hydrocephaly, was observed in
these mice (Table 1). As in our preliminary studies with dll137,
the tumors became life threatening much later than did those
induced by wild-type T antigen (averaging 30 weeks, compared
with 9 weeks with wild-type T antigen; Fig. 2A). No abnormal
phenotype was consistently observed in any other tissue of
these mice, including spleen and thymus.
Two founder mice that developed representative choroid
plexus tumors (LST1137-5 and -6) were used to establish
independent families of LST1137 mice for further analyses. All
transgenic mice in both lineages reproducibly developed CPE
tumors, reaching a life-threatening stage at an average of 6 to
7 months of age (Fig. 2B and Table 1). The fact that the
phenotype was 100% penetrant in the LST1137-5 and -6
lineages (Fig. 2B) suggests that the lower frequency of tumor
development in the LST1137 founder mice (50%, compared
with 75% with wild-type T antigen; Fig. 2A) most likely reflects
the influence of some insertion sites on transgene expression
(59) rather than the requirement for additional stochastic
events for tumorigenesis. In previous studies with dll137 and
with other mutants of T antigen, the founder mice that did not
develop a phenotype did not express the protein (5, 73).
Further characterization of brain tumor progression (de-
scribed below) supports this explanation.
Lymphoid abnormalities were not detected in LST1137
founder mice or in LST1137-5 or LST1137-6 transgenic off-
spring. Histological analysis showed spleens and thymuses to
be normal (data not shown). This result is in contrast with
those for mice harboring wild-type T antigen, which develop
both B- and T-cell abnormalities (6), and mice harboring
another mutant of T antigen (dll 135), which consistently
develop T-cell lymphoma (see Discussion and reference 73).
Fluorescence-activated cell sorting (FACS) analysis of thymo-
cytes from LST1137 animals (2 to 4 months of age) also
demonstrated a normal subset distribution (data not shown),
unlike mice of the same age undergoing T-antigen-induced
thymoma, which show a distinctly abnormal T-cell distribution
(73). In an even more sensitive assay, thymocytes from
LST1137 mice underwent normal irradiation-induced apopto-
sis, a pathway that is disrupted by a T-antigen variant that
consistently induces T-cell lymphoma (56).
d11137 is sufficient to induce abnormal growth of the choroid
plexus. The reproducible age at which full CPE expansion
occurred in mice from both LST1137-5 and -6 lines suggested
that only the amino-terminal 121 residues of T antigen were
required to induce the tumorigenic process in this cell type. On
the other hand, as was observed with LST1137 founder mice,
development of the phenotype was delayed considerably in
comparison with that induced by wild-type T antigen (compare
LST in Fig. 2A with Fig. 2B). To determine whether this
reflected the requirement for secondary somatic events, which
should lead to focal growth of tumors, we characterized the
morphological progression of abnormal changes in the CPE of
LST1137 mice from each family.
Figure 3 shows the representative morphology of the cho-
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FIG. 1. Diagrams of the LST1 137 and LST1 137K1 transgenes (A) and their encoded proteins (B). The ScaI-to-BamHI fragment containing the
respective LST fusion gene was used for the generation of transgenic mice. The fragment consists of the 580-bp LPV control region ( 1 ) and
the mutant SV40 T-antigen-coding region (FII). In panel A, shaded boxes represent exons. Linear diagrams of wild-type, dll137, and dll137K1
T antigens are shown in panel B. Regions involved in binding pRB, pl07, and p53 are indicated. X indicates a genetically defined transforming
activity whose corresponding biochemical function(s) has not been identified (73). Both dll 137 and dll 137K1 proteins encode the amino-terminal
region of T antigen (121 residues) followed by 11 missense amino acids (*). dll137K1 further contains a single amino acid change (E-107-*L) in
the pRB/p1O7 region. Both transgenes harbor a deletion of SV40 (from nucleotides 4854 to 4586) that disrupts the expression of small t antigen
as a result of removal of the small t-specific splice donor site (10). This mutation does not affect the expression of large T antigen since it lies
entirely within the large T intron.
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TABLE 1. Phenotypes of LST1137 and LST1137K1
transgenic micea















LST1137-5 CPT 14-44 (45/45)
LST1137-6 CPT 12-36 (11/11)
LST1137K1-3 Normal >37 (16/16)
LST1137K1-4 Normal >36 (11/11)
LST1137K1-5 Normal >38 (10/10)
a Pathological changes were observed during dissection and confirmed by
histological examinations. Mice indicated as normal were macroscopically nor-
mal at the time of sacrifice. Brain-related phenotypes are indicated as CPT
(choroid plexus tumor) and HC (hydrocephaly). Animals were sacrificed when
abnormalities were grossly apparent or near the end of the study. The LST1 137-1
to -4 and LST1137-9 to -13 founder mice were described previously (5). Four of
the 29 LST1 137K1 founder mice listed as normal died near 1 year of age with no
detectable abnormalities. Another apparently normal mouse (LST1137K1-2)
died of unknown causes at 17 weeks. A final LST1137K1 mouse which appeared
normal (LST1137K1-2) was sacrificed near the end of the study and found to
have a growth under the right forelimb which was not analyzed further. None of
the LST1 137K1 founder mice had detectable abnormalities in the choroid
plexus. All animals of lines LST1137K1-3, -4, and -5 sacrificed near the age
indicated were found to be phenotypically normal. These mice spanned gener-
ations 1 to 4, 1 to 6, and 1 to 3, respectively. ND, not determined.
roid plexus at the earliest (1 month after birth) and at one of
the latest (7 months) times examined; several more mice at
ages 1 to 9 months were also examined. Transgenic mice of
both LST1137-5 and LST1137-6 families consistently showed
abnormal morphology of the choroid plexus. By 1 month of
age, most epithelial cells in the choroid plexus appeared
crowded and highly abnormal, with reduced cytoplasm and
darkly stained nuclei sometimes of variable size (Fig. 3;
compare normal CPE in panel a with LST1137 CPE in panel
b). Usually at this early stage, the overall tissue organization
was retained and patchy areas of more normal-appearing cells
were often present (Fig. 3b). As the animals aged, the fourth
and two lateral ventricles of the brain continued the same
pattern of general expansion and morphological abnormalities
became more severe. Numerous giant and aberrantly shaped
nuclei were present, and the characteristic single-cell layer
organization was perturbed (Fig. 3c). Although the choroid
plexus of the third ventricle was clearly morphologically al-
tered, it did not appear to increase in size to the same extent,
perhaps because of the limited amount of tissue normally
present in this region of the brain (69). By 7 months of age, the
three ventricles were distended and filled with highly abnormal
anaplastic cells as had been observed with wild-type T antigen
at a much earlier age (6). Examination of several time points
showed no evidence of focal tumor growth that would indicate
the participation of secondary somatic mutations in tumor
induction.
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FIG. 2. Survival of LST, LST1137, and LST1137K1 transgenic
mice. Survival of founder mice is shown in panel A, and survival of
mice in the transgenic lineages LST1137-5 and -6 and LST1137K1-3,
-4, and -5 is shown in panel B. Mice born in several different litters
after the F5 generation were included in the survival curves. Animals
were sacrificed for analysis when death appeared imminent or after 12
months of age. The age of sacrifice versus the percentage of animals
surviving choroid plexus abnormalities was plotted. Mice determined
to be normal and sacrificed at 12 months are registered as survivors.
LST founder mice graphed in panel A express wild-type T antigen and
are described in reference 6. See Table 1 for further information on
each founder mouse that developed an abnormal phenotype.
normal mouse, there is a dramatic decrease in CPE cell
proliferation by birth and then complete cessation within the
first 2 weeks of life (52). In response to wild-type T antigen, the
entire choroid plexus remains proliferative throughout the
short life of the animal, with approximately 30% of the cells in
MOL. CELL. BIOL.











FIG. 3. Choroid plexus morphology in LST1137 and LST1137K1 transgenic mice. Brain sections were stained with hemotoxylin and eosin.
Shown is a representative lateral ventricle choroid plexus from a 5-month-old nontransgenic mouse (a), 1-month-old (b) and 7-month-old (c)
LST1137-6 mice, and a 5-month-old LST1137K1-5 transgenic mouse (d).
S phase at any given time (6). Another possible reason for later
appearance of tumors induced by dll137 was that although
cells were morphologically altered at a very early age, they did
not proliferate until secondary epigenetic changes occurred in
the animal. To determine whether cells were in fact progress-
ing through the cell cycle at early ages, we measured the
percentage of cells in S phase after BrdU incorporation in vivo
(Fig. 4). Cells undergoing DNA synthesis during the 2-h
labeling time were detected by using an antibody specific for
BrdU (see Materials and Methods). At 3 weeks of age, when
cells in S phase cannot be detected in normal choroid plexus
(6, 52) (identical to Fig. 4c), approximately 30% of the cells in
LST1137 choroid plexus were in S phase (Fig. 4a). This
number remained constant at later ages (4 months) when the
choroid plexus had clearly expanded (Fig. 4b). At each point
examined, the distribution of S-phase cells appeared random,
not focal, indicating uniform widespread abnormality, as mor-
phological examination had also suggested. These results
indicate that the amino-terminal 121-aa fragment of T antigen
is sufficient to induce abnormal cell proliferation, morpholog-
ical alteration, and expansion of the CPE comparable to that
induced by wild-type T antigen. Hence, the critical difference
in CPE tumors induced by wild-type and d11137 T antigens is
the overall rate of tumor growth. Possible mechanisms for a
decreased tumor growth rate in LST1 137 mice are explored in
Discussion.
The pRB/p107-binding region is critical for brain tumor
induction. Genetic studies in cultured cells have indicated that
the pRB/p107-binding region of T antigen is important for
transformation (see the introduction). Our preliminary work in
transgenic mice also indirectly implicated a role for this
activity(ies) in the induction of brain tumors (5). To further
test this hypothesis, we introduced into the LST1137 transgene
a single-base change (C-4500 to T) that results in a glutamic
acid-to-lysine mutation in the pRB/p107-binding region (aa
107). This alteration (35) has been shown to disrupt binding of
T antigen to both pRB and p107 (13, 21). The resulting gene
(LST1137K1), also under the control of the LPV transcrip-
tional signals (Fig. 1), was used to generate 31 transgenic
founder mice.
None of the LST1137K1 founder mice developed choroid
plexus abnormalities (Table 1). In fact, all but one mouse
survived to old age (Table 1). For more rigorous analyses,
three independent lines were generated from the LST1137
K1-3, -4, and -5 founder mice (Table 1 and Fig. 2B). Mice of
these lineages, like the majority of LST1137K1 founder mice,
had a normal phenotype. One animal in each line died of
unknown causes, although neither of them presented signs of
brain abnormalities (not shown). The remaining LST1137K1
transgenic animals which were not sacrificed for analysis (37
mice in all) survived to more than 8 months of age (Fig. 2B and
Table 1). The brains of four mice of different ages between 1
and 9 months were analyzed histologically for signs of abnor-
mality in the CPE. As with the founder LST1137K1 mice, no
abnormalities were detectable. A representative brain section
is shown in Fig. 3d. In contrast to the CPE of LST1137 mice
(Fig. 3b and c), where the cell morphology was highly aberrant
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FIG. 4. Proliferation of choroid plexus cells in transgenic mice.
Mice were treated with BrdU for 2 h before sacrifice, when brains were
frozen and sectioned as described in Materials and Methods. Cells
which had incorporated the label were detected after immunoperoxi-
dase staining with an antibody specific for BrdU. Shown are represen-
tative fields from a 3-week-old LST1 137-5 transgenic mouse (a), a
4-month-old LST1 137-6 transgenic mouse (b), and an 8-month-old
LST1137K1-5 transgenic mouse (c). In LST1137 mice of both ages,
approximately 30% of the choroid plexus cells were positive for the
BrdU signal. None of the cells examined from the LST1137K1 mice or
from nontransgenic age-matched controls (not shown) showed evi-
dence of BrdU incorporation.
animals of all ages was indistinguishable from that of normal
nontransgenic mice (compare panels Fig. 3a and d). Cells
retained the characteristic cuboidal morphology having regu-
larly shaped, uniformly stained nuclei and clearly detectable
cytoplasm. The normal papillary structure of the tissue was
also present.
To determine whether dll137K1 induced cell proliferation
at moderate levels that might escape detection by inspection of
overall morphology, the choroid plexus was examined for
evidence of replicating DNA as described above for LST1137
mice. None of the choroid plexus cells of an LST1137K1-5
mouse (8 months of age) incorporated the BrdU label, as
evidenced from the lack of detection with anti-BrdU antibody
(Fig. 4c). This result indicates that as in normal nontransgenic
mice beyond about 2 weeks of age, the CPE cells were not
induced to proliferate.
Normal expression ofd11137 and d11137K1. It was important
to demonstrate that the inability of dll 137 to induce B- and
T-cell abnormalities and the inability of dll137K1 to induce
CPE tumors reflected a property of the protein and was not
simply due to lack of protein expression. Several tissues from
mice of LST1137 and LST1137K1 lineages were examined for
protein expression by immunoblotting analysis. To ensure
specificity and to optimize sensitivity, the proteins were immu-
noprecipitated with antibodies specific to the N-terminal por-
tion of T antigen (PAb1O8 and PAb419; see Materials and
Methods) prior to detection by immunoblotting. A represen-
tative analysis is shown in Fig. 5A. As expected, both d11137
and dl1137K1 proteins were expressed in brains (Fig. 5A and
C) and in spleens and thymuses (Fig. 5B) of the transgenic but
not the nontransgenic control animals, a result consistent with
the specificity of the LPV regulatory region (4-6). Neither
protein was detected in other tissues, such as kidney and liver
(data not shown). The T-antigen variants were detected with
this specificity in all transgenic lines analyzed, although the
absolute levels differed for each particular tissue and line (Fig.
5B). Hence, although the two mutant proteins differed from
wild-type T antigen and from each other with respect to their
in vivo transforming abilities, their expression patterns were
the same. Furthermore, immunoprecipitation with an anti-p53
monoclonal antibody prior to immunoblotting confirmed that
neither dll 137 nor dll 137K1 associates with p53 in tissues (Fig.
5A, lanes 4 and 8).
Although dll137K1 was detected in brain despite of the lack
of abnormality, a formal possibility was that the level of
expression was significantly lower than that at which d11137
disrupts the growth of CPE cells. To determine whether this
was the case, protein expression was compared between
LST1137-5 mice (which consistently developed CPE tumors)
and LST1137K1-5 mice (which never developed abnormali-
ties). Since the CPE tissue of LST1137 mice expanded with
age, the brains of several young mice were examined in order
to compare levels of protein when a comparable amount of
CPE tissue was present. Although less informative, the level of
protein in total brain at later times was also assessed. During
the time prior to massive CPE expansion in LST1137 mice (1
to 3 months), comparable levels of the two proteins were
detected (Fig. SC). During this 1- to 3-month age period,
however, the dll 137-expressing cells were morphologically
altered (Fig. 3b) and were clearly proliferating abnormally
(Fig. 4a), while the dll 137K1-expressing cells remained normal
throughout the animal's life span (Fig. 3d and 4c). As antici-
pated, the amount of dll 137 protein present in total brain
increased subsequently with age (4 to 10 months; Fig. SC), in
correlation with the observed increase in the total amount of
choroid plexus tissue (Fig. 3c). In contrast, the constant
amount of CPE in total LST1137K1 brain at all times yielded
a constant level of dl1137K1 protein (Fig. SC).
In both cases, the T-antigen variants detected in brain were
localized to the choroid plexus, as evidenced from in situ
immunodetection using affinity-purified T-antigen-specific an-
tibodies (Fig. 6). As expected from the small size and lack of
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FIG. 5. Expression of d11137 and dl1137K1 proteins in transgenic mice. In panel A, the truncated T-antigen proteins in brain extracts of
LST1137-5 (15-week-old) and LST1137K1-5 (18-week-old) animals were detected by immunoblotting with an antibody specific for the amino
terminus of T antigen (PAblO8). Specific proteins were immunoprecipitated prior to immunoblotting with polyclonal hamster anti-T-antigen
antibody (lanes 1 and 5), anti-T-antigen monoclonal antibodies (PAb1O8 [lanes 2 and 6] and PAb419 [lanes 3 and 7]), or an anti-p53 antibody
(PAb421 [lanes 4 and 8]). The positions of heavy and light immunoglobulin subunits (IgH and IgL) are indicated. Purified baculovirus-produced
dlll37 protein served as a marker (middle lane; higher-molecular-weight forms present in this lane are most likely undenatured multimers of
dll137). In panel B, the relative amount of each mutant T-antigen (TAg) protein in spleens and thymuses was determined. The dll137 and
dll137K1 proteins were immunoprecipitated from 300 mg of total protein with polyclonal hamster anti-T-antigen antibody and detected by
immunoblotting as in panel A. The level of signal relative to that obtained from brain extract of a 5-month-old LST1 137-6 transgenic mouse (lane
2) was determined by densitometric analysis. The bands and quantified signals correspond to the following samples: nontransgenic brain (4 month,
lane 1), LST1137-6 brain (5 month, lane 2); LST1137-6 spleen (5 month, lane 3), LST1137K1-3 spleen (4 month old, lane 4; 1 year old, lane 5),
LST1137-6 thymus (5 month, lane 6), and LST1137K1-3 thymus (4 month, lane 7; 1 year, line 8). In panel C, the levels of dll137 and dll 137K1
proteins in brain tissue of mice at various ages were determined as described for panel B. Each bar represents the total amount of the T-antigen
(T Ag) protein present in an individual brain arbitrarily compared with the amount present in a LST1 137 7-month-old brain. LST1137-5 samples
are indicated with dark bars, and LST1137K1-5 samples are indicated with lighter bars. Two data sets (a and b) are shown. The values within a
set were determined in the same experiment. Two samples (from one 7-month-old LST1137K1 and one 10-month-old LST1137 mouse) showed
unusual protein levels which were not reproduced in further analysis of the same lines (data not shown).
were present in both the nuclei and cytoplasm. Cells through-
out the choroid plexus of LST1 137K1 mice stained uniformly,
indicating consistent levels of protein in most cells (Fig. 6b).
Most cells of the LST1 137 choroid plexus also showed a similar
pattern of staining, although the cell morphology was abnor-
mal (Fig. 6a). Within the LST1137 choroid plexus, a small
number of intensely stained cells with dense nuclei were
detected. Since similar cells were not observed in dlll37K1-
expressing tissue, the presence of these cells may reflect the
actively growing status of the LST1 137 choroid plexus. Further
experiments will be required to determine the significance of
this observation. Overall, although we cannot exclude the
possibility that subtle differences in protein levels exist between
LST1 137 and LST1137K1 mice, the in situ and immunoblot-
ting analyses of mutant T-antigen protein expression strongly
support the hypothesis that the induction of CPE tunors by
the dll 137 T antigen is dependent on the presence of an intact
domain of interaction with pRB and p107.
DISCUSSION
We have used the SV40 T antigen in transgenic mice as a
tool to determine the functions of its cellular targets and their
roles in tumorigenesis of different cell types. In this study, we
examined the tumorigenic capacity of a T-antigen fragment
that contains only the amino-terminal 121 aa and thus has no
ability to interact with p53 but retains the pRB/p107-binding
region. This fragment induces tumors in a cell-specific fashion;
i.e., the truncated T antigen is sufficient to induce choroid
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FIG. 6. In situ detection of dll137 and dll 137K1 proteins in the choroid plexus of transgenic mice. The proteins were visualized in 8-p.m brain
sections from a 3-week-old LST1137-5 mouse (a and c) and a 7.5-month-old LST1137K1-5 mouse (b and d) by indirect immunohistochemistry
(Materials and Methods), using an affinity-purified polyclonal hamster anti-T-antigen antibody (a and b). No signal was detected in the absence
of specific primary antibody treatment (c and d).
regulation in either B or T lymphoid cells. These observations
confirm and extend our previous analysis of T antigen variants
in transgenic mice (see below), indicating that the relative
contribution of T-antigen activities to tumorigenesis differ
according to the cell type and/or developmental stage. This
differential effect may reflect the use of different pathways for
growth regulation in each cell type or different requirements
for the establishment of abnormal tumor growth. In addition,
the cellular targets of T antigen may simply have different
functions depending on the cell type, stage of differentiation,
or cellular environment. The possible role of T-antigen func-
tions in each cell type examined is discussed below.
Role of pRB/plO7 binding in brain tumor induction. To
determine the critical activities involved in brain tumor induc-
tion present within the amino-terminal 121 aa of T antigen, we
directed a mutation (35) to a position that was shown previ-
ously to disrupt the pRB/p107-binding function of wild-type T
antigen (13, 21). The resulting dlll37K1 mutant was unable to
induce choroid plexus tumors, suggesting that interaction of T
antigen with pRB and/or p107 is essential to alter normal
growth of the CPE. The inability of dl1137K1 to induce CPE
abnormalities could not be explained by lower levels of protein
expression, as it was consistently and specifically expressed in
the choroid plexus at levels comparable to levels of dl137
expression (Fig. 5 and 6). From the current studies, we cannot
determine whether the critical function disrupted in dll 137K1
is the interaction with pRB or p107 or both. Moreover, this
mutation could change the protein conformation and disrupt
other activities in the amino terminus for which there is as yet
no biochemical assay (such as the activity known to reside
within the first 82 aa). Our studies would suggest, however, that
the interaction of one host protein, p185, with d1137 is not
sufficient for tumor induction, since this interaction was previ-
ously shown to be undisturbed by the Kl mutation (39).
Whether this and other amino-terminal T-antigen activities
play a role in tumor induction will require more extensive
analysis of the T-antigen amino-terminal fragment in trans-
genic mice.
The absence of abnormal cell division in the CPE of
LST1137K1 mice compared with LST1137 mice suggests that
the pRB/p107-binding function may either prevent cessation of
cell proliferation during CPE differentiation or inappropriately
initiate cell division after differentiation. Indeed, experiments
in cultured cells have shown that several properties of pRB are
consistent with a general role in cell cycle regulation (3, 7, 14,
18, 22, 25, 31; for reviews, see references 11, 27, and 58), and
recent reports suggest a similar function for p107 (84). How-
ever, the observed abnormalities in mice homozygous for a null
mutation in the Rb locus are limited and specific (8, 34, 44).
Arrested embryos (around embryonic days 12 to 14) show
abnormalities in the central nervous system, including the
presence of mitotic cells in nonmitotic zones and increased cell
death. The embryos also show signs of impaired hepatic
erythropoiesis, evidenced from the abundance of nucleated
erythrocytes in fetal liver (8, 34, 44). These results are more
consistent with pRB having a role in the differentiation of
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specific cell types, perhaps in regulating exit from a rapidly
dividing state. As adults, mice heterozygous for the null Rb
allele develop pituitary tumors with a loss of heterozygosity at
the Rb locus (34), again suggesting a cell-specific function. The
fact that CPE tumors have not been observed in these mice
might mean that tumorigenesis induced by T antigen requires
a function(s) in addition to binding pRB. For example, if p107
or some other protein provides functional redundancy, the
ability of T antigen to bind both pRB and p107 would be
critical for tumorigenesis. Our previous results also suggest the
importance in CPE tumorigenesis of an amino-terminal activ-
ity (disrupted by deletion of T-antigen aa 17 to 27) which is
distinct from pRB/p107 binding (73). Perhaps both T-antigen
activities must cooperate to produce tumors in the CPE.
Role of the T-antigen C terminus in brain tumor progres-
sion. The dll137 protein induced abnormal growth of the CPE
which was characteristic of wild-type T antigen; however, by
comparison, the phenotype was significantly delayed. This
delay could have resulted from a slower or nonuniform rate of
tumor growth or from the requirement for secondary cooper-
ating genetic or epigenetic events. If the truncated protein
encoded by dll 137 is sufficient to induce tumorigenesis, one
could expect all cells expressing this protein to be transformed
and to participate uniformly in tumor growth, as was the case
with wild-type T antigen in the CPE (6). On the other hand, if
the absence of some critical T-antigen activity in d11137 results
in insufficiency for tumor induction, requiring a compensating
cellular change, abnormal growth properties should be ob-
served only in those cells in which the secondary event took
place. Thus, tumors should develop focally after a period of
latency, which might vary depending on when the secondary
event(s) occurs. The phenotype of LST1137 mice did not
display these characteristics. Rather, the reproducible age at
which full CPE expansion occurred (Fig. 2) and the uniform
morphological progression of the tumors (Fig. 3) suggest that
dll137 is sufficient to induce abnormal choroid plexus cell
growth without dependence on cooperation.
The late phenotype did not reflect delayed onset of cell
proliferation or a lower percentage of proliferating cells com-
pared with wild-type T-antigen mice, as evidenced from exam-
ination of the tissue for S-phase cells (Fig. 4). By 3 weeks of
age, the normal nontransgenic choroid plexus is devoid of
S-phase cells. In contrast, about 30% of the choroid plexus
cells in a 3-week-old LST1137 mouse were in S phase, as
evidenced from BrdU incorporation into nuclei. Consistent
with morphological inspection, there were no signs of focal cell
cycle activity. The fraction of S-phase cells remained constant
at older ages when tumors were enlarged (4 months) and did
not vary from that previously determined for wild-type T-
antigen-expressing choroid plexus (6).
Hence, the tumors induced by dll 137 appear to have a much
lower growth rate than do those induced by wild-type T
antigen. Preliminary experiments suggest that the wild-type
rate of tumorigenesis is restored upon interbreeding LST1137
mice and transgenic mice that do not develop CPE abnormal-
ities (73) but which harbor a mutant T antigen (dll135)
containing an intact p53-binding C-terminal region (73a).
Hence, some function in the C-terminal four-fifths ofT antigen
has a role in regulating the rate of tumor formation, and that
function may be the ability to bind p53. We are currently
testing the hypothesis that p53 regulates the rate of epithelial
cell tumor growth by measuring the rate of d11137-induced
tumor growth in a p53 null mouse strain.
Current understanding of p53 function provides testable
hypotheses which may explain its putative contribution to
tumor growth rate. First, several recent observations suggest
that p53 may have a role in cell cycle checkpoint control. For
example, the levels of p53 increase in response to DNA
damage-inducing agents (36) in correlation with G, arrest (36,
40). Moreover, in several systems, conditional expression of
p53 induces G1 arrest (15,40,55, 75). In the absence of p53, G,
arrest fails (36) and the genome becomes unstable (48, 79).
Hence, p53 has been described as a "guardian of the genome,"
ensuring that only cells with intact genomes progress through
cell division (41). Binding of p53 by wild-type T antigen may
release such a control and allow aberrant cells to progress
through the cell cycle. Cells expressing the truncated dll137
protein would be abnormally transformed but would retain
normal p53 function and therefore may arrest or pause in G,.
Another series of observations provide an alternative, per-
haps complementary hypothesis to explain the slow growth of
d11137-induced CPE tumors. p53 has been shown to induce
programmed cell death, or apoptosis, in cultured cells (64, 80,
81), and thymocytes from p53 null mice fail to apoptose in
response to irradiation (9, 50). Hence, one outcome of p53-
induced growth arrest may be cell death (42). Since the rate of
tumor growth reflects the balance of cell division and cell
death, the p53-binding function ofT antigen may interfere with
apoptosis of choroid plexus cells which is perhaps triggered by
abnormal cell proliferation, resulting in rapidly growing tu-
mors. The d11137 protein would be able to induce the apop-
totic response but unable to interfere with this p53-mediated
pathway, resulting in abundant cell death and slower overall
growth of tumors. Morphological signs of apoptosis were in
fact visible in LST1 137 CPE (data not shown), although more
rigorous analysis is required to determine how this compares
with the phenotype induced by wild-type T antigen. A similar
mechanism has been described in cell culture experiments with
the adenovirus transforming proteins. In response to the ElA
protein (which, like d11137, binds pRB and p107), the cells
undergo apoptosis, a phenomenon that seems to be mediated
through p53 (12, 49). This response is inhibited by the E1B
gene products (12, 49). Further study of the T-antigen trans-
genic mice will determine whether such a mechanism contrib-
utes to tumor progression in vivo.
p53-binding function correlates with lymphomagenesis in-
duced by T antigen. Our work with mutant T-antigen proteins
suggests correspondence between the ability to bind p53 and
the ability to induce lymphomagenesis. In an earlier study, a
full-length mutant T antigen (5080) carrying a single amino
acid change (Pro-584 to Leu) that renders a protein unable to
bind p53 and pRB/p1O7 was impaired in lymphomagenesis (5).
This protein was not completely inactive, since it induced
hyperplasia (though not overt tumors) in the choroid plexus
(5). In contrast, T-cell lymphoma was consistently induced by a
T-antigen mutant (dll 135) which retained binding to all three
proteins but harbored a deletion of the amino-terminal-most
transformation activity (73). Interestingly, the latter mutant
appeared unable to induce B-cell tumors (73). Since dll 137
binds pRB and p107 but not p53, it was critical to determine
whether it had the capacity to induce lymphoma. As docu-
mented herein, neither B- nor T-cell tumors were produced in
any of the founder LST1 137 mice or their transgenic offspring.
Spleens and thymuses were histologically normal in spite of
demonstrable expression of the dll137 protein.
Since we previously characterized the progression of T-cell
lymphoma induced by the p53/pRB/plO7-binding form of T
antigen (73), we were able to rule out any detectable abnor-
malities in the T-cell population of LST1137 mice. Mice that
develop T-antigen-induced T-cell lymphoma begin to show an
abnormal distribution of T cells in the thymus after about 2
months of age. By 4 to 6 months of age, the mice show an
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overwhelming predominance of a single mature class of T cell
(either CD4+ CD8 - or CD4 - CD8+) in the thymus which is
eventually often abundant in the spleen. FACS analysis dem-
onstrated a normal thymocyte distribution in thymuses and a
normal T-cell distribution in spleens of LST1 137 mice of
various ages. Moreover, whereas thymocytes from mice ex-
pressing the p53-binding form of T antigen are protected from
irradiation-induced apoptosis, thymocytes from LST1 137 mice
apoptose normally (56). Because this same phenotype is
produced in mice with a homozygous null mutation in p53 (9,
50), this result also supports the hypothesis that the p53-
binding function of T antigen leads to p53 inactivation. In fact,
p53 null mice commonly develop T-cell lymphoma (17, 50),
supporting the interpretation that elimination of p53 is a
critical function of T antigen in tumorigenesis of this cell type.
Since induction of lymphoma by T antigen clearly requires
secondary events, unlike choroid plexus tumorigenesis, one
possibility is that the p53-binding function disrupts a p53-
dependent surveillance pathway which under normal condi-
tions would lead to the death of cells with accumulated
mutations. Such a pathway could be essential in cells such as
lymphocytes which undergo frequent DNA rearrangements.
Disruption of p53 function, either by T antigen or by mutation,
leads to survival of cells which have undergone secondary
mutations that may lead to tumor progression.
In summary, the development of transgenic mice has facili-
tated the examination of certain cellular functions which are
common targets for DNA virus transforming proteins. In this
report, we suggest that the pRB/p107-binding region of T
antigen has an essential role in subverting choroid plexus cell
growth control whereas the p53-binding function is dispens-
able. In contrast, a C-terminal T-antigen function, possibly p53
binding, is required to perturb normal lymphoid cell growth
and may also be involved in accelerating the oncogenic process
in the choroid plexus. Similar experiments in which various
T-antigen mutants are directed to other specific cell types and
developmental stages in transgenic mice, combined with the
use of mice carrying null mutations in the cellular target genes,
should yield a more complete analysis of these functions in
tumorigenesis and development.
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